GlassScriptPhysician profile
Kyle Marshall
NPI 1306445432
$1,403.66
in general payments reported to CMS, 2019-2025
14 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.70 · 2022: $258 · 2023: $223 · 2024: $404 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $423.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $330.01 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $172.65 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $98.14 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.80 | 2022 | |
| Glaxosmithkline, LLC. | $48.36 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $47.02 | 2024-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $45.62 | 2021 | |
| Exact Sciences Corporation | $42.94 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $41.35 | 2022 | |
| Genentech USA, INC. | $30.59 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $19.23 | 2023 | Gvoke Hypopen |
| Gilead Sciences, INC. | $19.17 | 2022 | |
| Currax Pharmaceuticals LLC | $14.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.